Recent publications
Publications
-
Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?
Part of Expert Opinion on Biological Therapy, p. 115-117, 2023.
-
Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines
Part of Brain Communications, 2023.
DOI for Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines Download full text (pdf) of Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines
-
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Part of BMC Cancer, 2023.
DOI for Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer Download full text (pdf) of Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
-
Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
Part of Immunity, Inflammation and Disease, 2022.
DOI for Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology Download full text (pdf) of Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
-
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
Part of Vaccines, 2022.
DOI for Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines Download full text (pdf) of Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
-
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
Part of Journal for ImmunoTherapy of Cancer, 2022.
DOI for Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials Download full text (pdf) of Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
-
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
Part of Journal of Internal Medicine, p. 72-80, 2022.
DOI for Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19 Download full text (pdf) of Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
-
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
Part of Lancet. Infectious diseases (Print), p. 943-945, 2022.
-
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
Part of JAMA Network Open, 2022.
DOI for Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab Download full text (pdf) of Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
-
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
Part of Journal of Translational Medicine, 2022.
DOI for Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination Download full text (pdf) of Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
-
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
Part of Clinical & Translational Immunology (CTI), 2022.
DOI for Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time Download full text (pdf) of Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
-
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
Part of PLOS ONE, 2022.
DOI for SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection Download full text (pdf) of SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
-
An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Part of Advanced Therapeutics, 2022.
DOI for An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies Download full text (pdf) of An Adaptable Antibody-Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
-
Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
Part of International Immunopharmacology, 2021.
DOI for Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients Download full text (pdf) of Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients
-
Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers
Part of Journal of the American Medical Association (JAMA), p. 2015-2016, 2021.
-
Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
Part of New Biotechnology, p. 9-19, 2021.
DOI for Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells Download full text (pdf) of Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
-
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
Part of EBioMedicine, 2021.
DOI for Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 Download full text (pdf) of Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
-
Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
Part of PLOS ONE, 2021.
DOI for Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations Download full text (pdf) of Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
-
An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
Part of PLOS ONE, 2021.
DOI for An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses Download full text (pdf) of An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
-
Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
Part of Journal of Pathology, p. 243-256, 2021.
DOI for Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer Download full text (pdf) of Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer
-
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Part of Cancers, 2021.
DOI for Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade Download full text (pdf) of Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
-
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Part of Nature Communications, 2021.
DOI for Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma Download full text (pdf) of Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
-
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Part of Oncoimmunology, 2020.
DOI for Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy Download full text (pdf) of Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
-
Flodvåg av långtidssjuka covid-19-patienter väntar
Part of Dagens Nyheter, p. 5-5, 2020.
-
Tumor localized agonistic anti-CD40 therapy and beyond
Part of Expert Opinion on Biological Therapy, p. 215-217, 2020.
DOI for Tumor localized agonistic anti-CD40 therapy and beyond
-
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Part of Toxicology reports, p. 768-771, 2020.
DOI for Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention Download full text (pdf) of Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
-
BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling
Part of Molecular Oncology, p. 202-211, 2019.
DOI for BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling Download full text (pdf) of BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling
-
Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System
Part of Journal of Immunology, p. 87-97, 2018.
-
Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics
Part of International Immunopharmacology, p. 1-11, 2018.
DOI for Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics Download full text (pdf) of Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics
-
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
Part of Gene Therapy, p. 92-103, 2017.
DOI for Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Download full text (pdf) of Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
-
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Part of Journal of Translational Medicine, 2017.
DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
-
Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Part of Scandinavian Journal of Immunology, p. 337-337, 2017.
-
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
Part of European Journal of Immunology, p. 385-393, 2017.
-
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
Part of OncoTarget, p. 78573-78587, 2017.
DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
-
Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies
Part of Translational Cancer Research, p. S839-S841, 2016.
DOI for Selective Fc gamma R engagement by human agonistic anti-CD40 antibodies
-
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
Part of OncoTarget, p. 50277-50289, 2016.
DOI for Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment Download full text (pdf) of Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
-
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015.
-
Kick-starting the cancer-immunity cycle by targeting CD40
Part of Oncoimmunology, 2015.
DOI for Kick-starting the cancer-immunity cycle by targeting CD40
-
Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells
Part of Scientific Reports, 2015.
DOI for Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells Download full text (pdf) of Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells
-
The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
Part of Journal of Neuroimmunology, p. 153-159, 2014.
-
Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
Part of Journal of Neuroimmunology, p. 141-141, 2014.
DOI for Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
-
FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis
Part of Journal of Immunology, p. 5540-5547, 2014.
DOI for FcγRIIb on myeloid cells rather than on B cells protects from collagen-induced arthritis
-
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer
Part of Cancer Immunology Research, p. 80-90, 2014.
DOI for Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer Download full text (pdf) of Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer
-
AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma
Part of Molecular Therapy, p. S247-S247, 2014.